Long Non-coding RNA Nuclear Enriched Abundant Transcript 1 (NEAT1) Sponges MicroRNA-124-3p to Up-regulate Phosphodiesterase 4B (PDE4B) to Accelerate the Progression of Parkinson's Disease
Overview
Affiliations
Reportedly, long non-coding RNA (lncRNA) are crucial modulators in neurodegenerative diseases. Herein, we investigated the role of lncRNA nuclear enriched abundant transcript 1 (NEAT1) in Parkinson's disease (PD). PD model was established based on SH-SY5Y cells treated with 1-methyl-4-phenylpyridinium (MPP+). NEAT1, microRNA (miR) -124-3p and phosphodiesterase 4B (PDE4B) expression levels were examined by qRT-PCR. CCK-8 assay and LDH release assay were adopted to delve into the cell viability and cytotoxicity, respectively. Besides, western blot was utilized to determine mTOR, p-mTOR and PDE4B expression levels. ELISA was executed to detect the levels of tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β) and interleukin 6 (IL-6). Dual-luciferase reporter assay and RIP assay were used to probe the relationship between miR-124-3p and NEAT1 or PDE4B. We demonstrated that, in SH-SY5Y cells treated with MPP+, NEAT1 and PDE4B expression levels were raised, while miR-124-3p expression was repressed; NEAT1 depletion or miR-124-3p overexpression increased the cell viability and suppressed cell injury. Besides, miR-124-3p was confirmed as the direct target of NEAT1, and its down-regulation counteracted the impact of NEAT1 depletion on SH-SY5Y cells. PDE4B was as the downstream target of miR-124-3p, and its overexpression weakens the impact of miR-124-3p on SH-SY5Y cells. Additionally, NEAT1 decoyed miR-124-3p to modulate PDE4B expression. Collectively, in MPP+-induced SH-SY5Y cells, NEAT1 depletion increases cell viability, represses cytotoxicity and reduces inflammatory response by regulating miR-124-3p and PDE4B expression levels, suggesting that NEAT1 may be a promising target for treating PD.
Gao Q, Li X, Huang T, Gao L, Wang S, Deng Y Aging (Albany NY). 2024; 16(21):13304-13322.
PMID: 39422618 PMC: 11719108. DOI: 10.18632/aging.206028.
Research progress on phosphodiesterase 4 inhibitors in central nervous system diseases.
Adili A, Dilihumaer A, Zhu H, Tang H Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024; 53(3):390-398.
PMID: 38860393 PMC: 11348698. DOI: 10.3724/zdxbyxb-2024-0023.
Meccariello R, Carlo Bellenchi G, Pulcrano S, DAddario S, Tafuri D, Mercuri N Front Cell Neurosci. 2024; 17:1328269.
PMID: 38249528 PMC: 10796818. DOI: 10.3389/fncel.2023.1328269.
Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential.
Roy D, Balasubramanian S, Krishnamurthy P, Sola P, Rymbai E Cell Mol Neurobiol. 2023; 43(6):2713-2741.
PMID: 37074485 PMC: 11410141. DOI: 10.1007/s10571-023-01349-1.
Crosstalk between regulatory non-coding RNAs and oxidative stress in Parkinson's disease.
Zhang H, Liu X, Liu Y, Liu J, Gong X, Li G Front Aging Neurosci. 2022; 14:975248.
PMID: 36016854 PMC: 9396353. DOI: 10.3389/fnagi.2022.975248.